CLONAZEPAM--DEA SCHEDULE IV ITEM (C005B-020854)

Biochem/physiol Actions

Anticonvulsant; ligand for the GABA_A receptor benzodiazepine modulatory site.

Features and Benefits

This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Molecular Weight: 315.71. Empirical Formula: C₁₅H₁₀ClN₃O₃. form: powder. Quality Level: 200. drug control: USDEA Schedule IV. Home Office Schedule 4.1. psychotrope (France). kontrollierte Droge in Deutschland. regulated under CDSA - not available from Sigma-Aldrich Canada. psicótropo (Spain). Decreto Lei 15/93: Tabela IV (Portugal). color: light yellow. originator: Roche. SMILES string: Clc1ccccc1C2: NCC(: O)Nc3ccc(cc23)N(: O): O. InChI: 1S/C15H10ClN3O3/c16-12-4-2-1-3-10(12)15-11-7-9(19(21)22)5-6-13(11)18-14(20)8-17-15/h1-7H,8H2,(H,18,20). InChI key: DGBIGWXXNGSACT-UHFFFAOYSA-N. Gene Information: human ... GABRA1(2554), GABRA2(2555), GABRA3(2556), GABRA4(2557), GABRA5(2558), GABRA6(2559), GABRB1(2560), GABRB2(2561), GABRB3(2562), GABRD(2563), GABRE(2564), GABRG1(2565), GABRG2(2566), GABRG3(2567), GABRP(2568), GABRQ(55879)
rat ... Tspo(24230). Storage Class Code: 11 - Combustible Solids. WGK: WGK 2. Flash Point(F): Not applicable. Flash Point(C): Not applicable. Personal Protective Equipment: Eyeshields, Gloves, type N95 (US).